GlassScriptPhysician profile
Khaja Kamal Mohiuddin
NPI 1669931598
$5,886.99
in general payments reported to CMS, 2019-2025
35 companies · $1,910 in 2025
The $1,910 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.93 · 2020: $55.17 · 2021: $57.34 · 2022: $52.47 · 2023: $2,338 · 2024: $1,445 · 2025: $1,910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,693.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $697.91 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $663.12 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $652.22 | 2023-2025 | |
| Pfizer INC. | $490.62 | 2021-2025 | |
| Amgen INC. | $481.79 | 2022-2025 | Repatha, Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $377.45 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $337.53 | 2019-2025 | Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $323.42 | 2023-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $298.25 | 2023-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $255.17 | 2022-2025 | Jardiance |
| Sumitomo Pharma America, INC. | $168.37 | 2024-2025 | Gemtesa |
| Glaxosmithkline, LLC. | $139.95 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Exact Sciences Corporation | $129.27 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $76.40 | 2023-2025 | Veozah |
| Merck Sharp & Dohme LLC | $69.95 | 2021-2023 | Verquvo, Belsomra, Steglatro |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khaja Mohiuddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.